Onconetix™ Chief Executive Officer Dr. Neil J. Campbell Issues Letter to Shareholders
19 déc. 2023 07h00 HE
|
Onconetix, Inc.
CINCINNATI, Dec. 19, 2023 (GLOBE NEWSWIRE) -- Onconetix, Inc., (Nasdaq: BWV) ("Onconetix" or the “Company”) today issued the following shareholder letter from the Company’s Chief Executive Officer,...
Blue Water Biotech Acquires Proteomedix as Part of Transformation to Commercial Stage Oncology Company; Announces Name Change to Onconetix™
18 déc. 2023 07h00 HE
|
Onconetix, Inc.
CINCINNATI, Dec. 18, 2023 (GLOBE NEWSWIRE) -- Blue Water Biotech, Inc. (Nasdaq: BWV) ("BWB" or the “Company”) today announced the acquisition of Proteomedix AG, a private, commercial-stage...
Blue Water Biotech Appoints Board-Certified Urologist Jay Newmark, M.D., MBA as Chief Medical Officer
26 avr. 2023 15h44 HE
|
Blue Water Biotech, Inc.
CINCINNATI, April 26, 2023 (GLOBE NEWSWIRE) -- Blue Water Biotech, Inc. (“Blue Water” or the “Company”), a biotechnology company spanning multiple sectors, today announced the appointment of Jay...
Blue Water Announces Acquisition of ENTADFI®, an FDA-Approved Benign Prostatic Hyperplasia Asset
20 avr. 2023 07h30 HE
|
Blue Water Vaccines Inc.
Acquisition Transforms the Company into a Broader Pharmaceutical Company Spanning Multiple Sectors Company Announces Corporate Name Change to Underscore Broader Focus Company to Host a Conference...
Midwest Institute for Non-Surgical Therapy (MINT) Introduces New Therapy to Treat Men With Enlarged Prostates
21 oct. 2022 09h00 HE
|
The Midwest Institute for Nonsurgical Therapy
ST. LOUIS, Oct. 21, 2022 (GLOBE NEWSWIRE) -- Midwest Institute for Non-surgical Therapy (MINT) has introduced a new therapy to treat men with benign prostatic hyperplasia (BPH). The condition, which...
Benign Prostatic Hyperplasic Devices Market Worth $3.46Bn by 2028 at 7.6% CAGR Lead by Urology Lasers Segment (Highest CAGR of 8.4%) Global Analysis by The Insight Partners
22 juil. 2022 08h26 HE
|
The Insight Partners
New York, July 22, 2022 (GLOBE NEWSWIRE) -- The Insight Partners published latest research study on “Benign Prostatic Hyperplasic Devices Market Forecast to 2028 - COVID-19 Impact and Global...
Fuisz Pharma LLC Announces Patent Issuance for its Non-Invasive Urological Device to Mitigate the Symptoms of Benign Prostate Hyperplasia (BPH)
18 avr. 2022 08h00 HE
|
FUISZ LLC
Williamson County, TN, April 18, 2022 (GLOBE NEWSWIRE) -- Fuisz Pharma LLC, an affiliate of Fuisz LLC, today announced the first patent issuance for its non-invasive urological device platform to...
Tricol Biomedical Receives NIH Phase IIB Grant to Continue Development of its Hemostatic Device for the Prostate
07 oct. 2021 11h00 HE
|
Tricol Biomedical
Portland, OR, Oct. 07, 2021 (GLOBE NEWSWIRE) -- Tricol Biomedical, a privately held medical device company dedicated to saving lives through innovative hemostatic and wound care solutions, has...
Zenflow Launches Pivotal Clinical Trial of Minimally Invasive Spring® Treatment for Enlarged Prostate Symptoms
04 oct. 2021 12h00 HE
|
Zenflow
SOUTH SAN FRANCISCO, Calif., Oct. 04, 2021 (GLOBE NEWSWIRE) -- Zenflow, Inc., a medical device company developing a minimally invasive treatment for enlarged prostate, or benign prostatic...
Zenflow Announces $24 Million Financing Round; Appoints Susan Stimson as President
02 juin 2021 09h00 HE
|
Zenflow
SOUTH SAN FRANCISCO, Calif., June 02, 2021 (GLOBE NEWSWIRE) -- Zenflow, Inc., a medical device company developing a minimally invasive treatment for urinary obstruction caused by enlarged prostate,...